You are here: Industry Insights > imdevimab

News List

FDA approve emergency use of REGEN-COVTM for COVID-19 prevention europeanpharmaceuticalreview
August 03, 2021
The FDA have authorised REGEN-COV monoclonal antibody therapy for emergency use as prevention for COVID-19 in certain patients.
Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 prnewswire
July 21, 2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron's casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19.
Chugai Pharma obtains regulatory approval for anti-SARS-CoV-2 monoclonal antibody Ronapreve expresspharma
July 21, 2021
The special approval for emergency under article 14-3 of the Pharmaceuticals and Medical Devices Act was applied to this approval.
FDA updates Regeneron’s Covid-19 antibody EUA to lower dose pharmaceutical-technology
June 07, 2021
The US Food and Drug Administration (FDA) has updated the Emergency Use Authorization (EUA) for Regeneron Pharmaceuticals’ Covid-19 antibody cocktail, REGEN-COV, reducing the dose to 1,200mg from 2,400mg.
Cipla to market Roche’s antibody cocktail pan-India, first batch currently available expresspharma
May 25, 2021
Casirivimab and Imdevimab is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in patients who are at high risk of severe COVID-19.
Roche’s antibody cocktail for COVID-19 may face affordability issues in India: GlobalData expresspharma
May 08, 2021
Following the news that Roche has received emergency use authorization (EUA) for a COVID-19 antibody cocktail casirivimab and imdevimab; Prashant Khadayate, Pharma Analyst at GlobalData offers his view.
Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% worldpharmanews
April 14, 2021
Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability of the investigational antibody cocktail casirivimab and imdevimab to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 ...
Roche’s antibody cocktail lowers hospitalisation by 70% in Covid-19 patients pharmaceutical-technology
March 24, 2021
Roche has reported that the Phase III REGN-COV 2067 trial of investigational antibody cocktail of casirivimab and imdevimab met its primary endpoint of reducing the risk of hospitalisation or death in treating high-risk, non-hospitalised Covid-19 ...
US could purchase over 1.5 million doses of Regeneron’s COVID-19 antibody cocktail europeanpharmaceuticalreview
January 19, 2021
The additional doses of casirivimab and imdevimab, two monoclonal antibodies, will be used in non-hospitalised COVID-19 patients.
Regeneron Announces Initial Data from COVID-19 Antibody Cocktail Trial americanpharmaceuticalreview
December 31, 2020
Regeneron Pharmaceuticals has announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.

Previous page 1 2 Next page